Arovella Therapeutics is focused on the immunoncology space (in particular cell therapies) following the in-licensing in CY21 of two chimeric antigen receptor (CAR) based immunotherapies (both in preclinical stage). The first was an invariant natural killer T (iNKT) cell therapy platform in-licensed from Imperial College London in July 2021. The platform can be combined with CARs to target blood cancers, with a potential of being an allogeneic ‘off-the-shelf’ therapy. This was followed by the in-licensing of a novel monoclonal antibody targeting a Dickkopf-1 (DKK1) peptide from MD Anderson Cancer Center in December 2021. Arovella plans to combine the DKK1 targeting technology with the iNKT cell therapy platform in future. In September 2022, Arovella signed a strategic collaboration with Imugene to investigate the combined potential of the company’s lead CAR19-iNKT programme ALA-101 with Imugene’s onCARlytics (CF33-CD19) platform in treating solid tumours. Following this the company has decided to cease all R&D activities related to its legacy OroMist platform.